Related Experiment Video
Updated: Apr 25, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
20.8K
[Transitional cell carcinoma of the bladder: bladder-sparing therapy]
F Vom Dorp1, S Tschirdewahn, T Szarvas
1Urologische Klinik, Helios Klinikum Duisburg, Duisburg, Deutschland.
Der Urologe. Ausg. A
|August 24, 2014
Summary
Transitional cell carcinoma of the bladder is often treatable with bladder preservation. For aggressive tumors, radical cystectomy
Area of Science:
- Uro-oncology
- Surgical oncology
- Genitourinary pathology
Context:
- Transitional cell carcinoma (TCC) represents the majority of bladder cancer cases.
- Treatment decisions for TCC involve balancing oncological outcomes with quality of life.
- Tumor characteristics like aggressiveness and genetic stability influence treatment efficacy.
Purpose:
- To evaluate the oncological safety and efficacy of different treatment modalities for transitional cell carcinoma of the bladder.
- To assess the role of radical cystectomy versus bladder-sparing approaches.
- To explore the outcomes of prostate-sparing surgery in select patient populations.
Summary:
- Transurethral resection and bladder preservation are safe for most bladder transitional cell carcinomas.
- Radical cystectomy's benefit for aggressive tumors is linked to tumor volume and resectability.
- Prostate-sparing surgery demonstrates oncological safety and good quality of life in appropriate candidates.
Impact:
- Informs clinical decision-making for bladder cancer management.
- Highlights the importance of personalized treatment strategies based on tumor characteristics.
- Supports the consideration of less invasive surgical options when oncologically feasible.
